Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cartesian Therapeutics, Inc. (RNAC : NSDQ)

• Company Description    Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass. Number of Employees: 75

• Price / Volume Information    Yesterday's Closing Price: $9.27 Daily Weekly Monthly 20 Day Moving Average: 112,574 shares Shares Outstanding: 30.25 (millions) Market Capitalization: $280.47 (millions) Beta: 0.62 52 Week High: $11.00 52 Week Low: $5.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.82% 6.30% 12 Week 7.79% 5.50% Year To Date 28.57% 14.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7495 New Horizon Way - Frederick,MD 21703 USA ph: 301-348-8698 fax: 617-924-3454 megan.leduc@cartesiantx.com http://www.cartesiantherapeutics.com

• General Corporate Information    Officers Carsten Brunn - President; Chief Executive Officer and Chairman Blaine Davis - Chief Financial Officer Patrick Zenner - Director Timothy C. Barabe - Director Adrian Bot - Director Peer Information Cartesian Therapeutics, Inc. (CORR.) Cartesian Therapeutics, Inc. (RSPI) Cartesian Therapeutics, Inc. (CGXP) Cartesian Therapeutics, Inc. (BGEN) Cartesian Therapeutics, Inc. (GTBP) Cartesian Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 816212302 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 30.25 Most Recent Split Date: 4.00 (0.03:1) Beta: 0.62 Market Capitalization: $280.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 158.01 EPS Growth vs. Year Ago Period: -8.00% vs. Previous Quarter: 131.51% Sales Growth vs. Year Ago Period: -92.91% vs. Previous Quarter: -91.76% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - -29.84 03/31/26 - -28.25 12/31/25 - -20.07 Current Ratio 06/30/26 - 7.48 03/31/26 - 7.65 12/31/25 - 8.65 Quick Ratio 06/30/26 - 7.48 03/31/26 - 7.65 12/31/25 - 8.65 Operating Margin 06/30/26 - - 03/31/26 - -5,356.28 12/31/25 - -2,631.46 Net Margin 06/30/26 - - 03/31/26 - -8,550.65 12/31/25 - -4,658.63 Pre-Tax Margin 06/30/26 - -10,906.16 03/31/26 - -9,068.56 12/31/25 - -4,987.31 Book Value 06/30/26 - -4.26 03/31/26 - -5.04 12/31/25 - -4.85 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©